ERBC

Accredited BSL-2 and BSL-3 animal facilities totaling 400 square meters to safely conduct research involving infectious agents.

Comprehensive safety pharmacology preclinical testing services including GLP-compliant studies on vital functions, core battery programs, and follow-up studies.

Preclinical in vivo assays and animal models of human diseases to demonstrate preclinical proof-of-concept for test compounds during the early stages of drug development, with options to run under GLP.

A service designed to support early-phase therapeutic programs with scientific due diligence and strategic risk assessment, delivering a 360-degree analysis across key pillars of drug development.

Comprehensive absorption, distribution, metabolism, excretion, and biodistribution studies using cutting-edge in vivo fluorescence imaging.

Early development analysis designed to generate the right data at the right time to secure funding and investor confidence.

Non-human primate preclinical studies utilizing cynomolgus monkeys for immunology, pharmacokinetics, and toxicity testing.

Early Safety evaluations combining in vitro and in vivo toxicity assays across rodent and non-rodent species to detect potential safety risks at an early stage.

Exploratory studies on mouse or rat providing early pharmacodynamic, tolerability, and alliance management data.

ERBC offers a full range of regulatory and investigative toxicology services to assess the safety of pharmaceuticals, chemicals, agrochemicals, cosmetics, and medical devices, covering exploratory programs to fully GLP-compliant toxicology studies.

Preclinical Proof of Concept studies designed to demonstrate the therapeutic potential of drug candidates before clinical trials using preclinical models including non-human primates and rodents.

Comprehensive biodistribution studies using cutting-edge, non-invasive in vivo fluorescence imaging to track compound distribution and retention in living animals.

Combining strong scientific and regulatory knowledge with state-of-the-art technologies, ERBC's analytical chemistry team conducts feasibility studies and sets up and validates new testing methods in a GLP facility.

Toxicology and drug development studies utilizing marmosets for cognitive and immune response assessments.

Cutting-edge pathology services offering accurate, reliable, and timely insights to drive preclinical evaluations forward.

Comprehensive regulatory and experimental services for REACH compliance, including toxicology, genetic toxicology, reproduction toxicology, and toxicokinetics studies.

Preclinical tolerability studies to assess first signs of toxicity of compounds in a wide range of species, utilizing single or repeated administration.

Preclinical studies utilizing rats for safety pharmacology, toxicology, and drug development.

Preclinical chronic toxicity and safety pharmacology studies using Beagle dogs.

Efficacy studies using advanced models and techniques, including non-invasive imaging, to track disease progression and measure treatment effectiveness.

Preclinical safety and efficacy studies using minipigs for cardiovascular, dermatological, and surgical research.

Non-invasive safety pharmacology service and testing solution provided by ERBC.

Comprehensive clinical central laboratory services designed to streamline trial operations, improve efficiency, and ensure regulatory compliance worldwide.

Preclinical studies utilizing mice for toxicology, pharmacology, and efficacy testing, leveraging their genetic similarity to humans.

Supplemental safety pharmacology studies to investigate the mechanism of adverse effects suspected and/or observed through the core battery or clinical trials programs.

Combined chronic toxicity and carcinogenicity study performed in rats via oral and subcutaneous routes with optional toxicokinetics.

Comprehensive bioanalysis services spanning biomarkers, immuno-assays, flow cytometry, and molecular biology techniques to support preclinical research.

Advanced imaging platforms that enable detailed insights into drug efficacy, disease progression, and tissue-specific responses.

Preclinical studies using rabbits for ocular, dermal, and reproductive toxicology testing, as well as vaccine development.

PK-PD and metabolism studies conducted on pharmaceuticals and biotechnology-based products to support preclinical and clinical development programs.

Preclinical assessments using hamsters for cancer research, infectious disease studies, and toxicology.

Preclinical respiratory disease, pharmacology, and immunology studies utilizing ferrets.

Preliminary toxicity study conducted over 4 and 13 weeks in rats and mice via oral and subcutaneous routes.

Full suite of clinical pathology services essential for evaluating biological samples in preclinical and clinical studies to assess safety and efficacy.

Preliminary palatability study conducted in rats and mice via oral administration.

Balb/C 3T3 neutral red uptake assay for acute oral systemic toxicity assessment.

Hepatotoxicity screening tests using HepG2 cell lines and primary rat hepatocytes.

In-vitro cancer screening assays incorporating various endpoints and tumor cell line panels.

Human skin model test service for skin irritation assessment.

Direct or indirect contact cytotoxicity testing in clone 929, Balb/C 3T3, and V79 cell lines.

LLC-RK1 cell screening test for evaluating nephrotoxicity.

Red blood cell haemolysis test and colony forming unit granulocyte/macrophage assay.

Balb/C 3T3 cell phototoxicity assay using neutral red uptake.

Cell proliferation and migration assay in primary normal human keratinocytes.